Free Trial
Fall Lock-In Sale! MarketBeat All Access, $149 a Year for Life
Lock In $149
Claim MarketBeat All Access Sale Promotion

Citigroup's Rating of Rapport Therapeutics on 10/20/2026

On October 20, 2026, Citigroup updated its outlook on Rapport Therapeutics (NASDAQ:RAPP) with the action "Reiterated Rating", keeping a "Outperform" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Citigroup Inc.

DateCompanyAction
10/20/2026
Braze, Inc. stock logo
BRZE
Braze
Downgrade
10/20/2026
Brunello Cucinelli S.p.A. - Unsponsored ADR stock logo
BCUCY
Brunello Cucinelli
Reiterated Rating
10/20/2026
SPS Commerce, Inc. stock logo
SPSC
SPS Commerce
Reiterated Rating
10/20/2026
Manhattan Associates, Inc. stock logo
MANH
Manhattan Associates
Boost Price Target
10/20/2026
Entegris, Inc. stock logo
ENTG
Entegris
Boost Price Target
10/20/2026
Starbucks Corporation stock logo
SBUX
Starbucks
Reiterated Rating
More Ratings From Citigroup Inc.